#ESMO26 #Tarlatamab 👇
73 views · 1 like · 0 reposts · 1 reply
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgLet’s take a look at #DeLLphi-305: the trial yields poor results in the "Americas," so you bring in a large number of Asian patients (±40%) #sclc #ESMO26 Opinions??? @StephenVLiu @drshieldsmd @Tony_Calles @LuisPaz_Ares @lungoncdoc @Annechiangmd @LealTiciana @latina @MartinReck2在 X 查看被引用的帖子
- Antonio G.@antonioonlinegm
@pistoto2017 Pues si el mercado más potente sus resultados son peores poco mercado le quitará a jazz con la lurbi. Y si donde es mejor es con asiáticos y en china te pagan más bien poco parece q la cosa no será para tanto. Arañar va arañar mercado eso sin duda. Lurbi se puede qdar con 50%
Source: FJ ⭐️⭐️+⭐️ · x.com